World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA

Eugen Dhimolea Dana Farber Cancer Institute; Harvard Medical School; Boston, MA USA

Janice M. Reichert Landes Bioscience; Austin, TX USACorrespondence[email protected]

Pages 4-13 | Received 15 Nov 2011, Accepted 15 Nov 2011, Published online: 01 Jan 2012

Cite this article
https://doi.org/10.4161/mabs.4.1.18821

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100:690 - 697; PMID: 12209608; http://dx.doi.org/10.1002/ijc.10557
PubMed Web of Science ®Google Scholar
Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115:98 - 104; PMID: 15688411; http://dx.doi.org/10.1002/ijc.20908
PubMed Web of Science ®Google Scholar
Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763 - 771; PMID: 16360021; http://dx.doi.org/10.1016/j.molimm.2005.03.007
PubMed Web of Science ®Google Scholar
Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007; 56:1551 - 1563; PMID: 17310380; http://dx.doi.org/10.1007/s00262-007-0298-z
PubMed Web of Science ®Google Scholar
Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214:441 - 453; PMID: 19157637; http://dx.doi.org/10.1016/j.imbio.2008.11.014
PubMed Web of Science ®Google Scholar
LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112:1570 - 1580; PMID: 18725575; http://dx.doi.org/10.1182/blood-2008-02-078071
PubMed Web of Science ®Google Scholar
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974 - 977; PMID: 18703743; http://dx.doi.org/10.1126/science.1158545
PubMed Web of Science ®Google Scholar
Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111:1827 - 1833; PMID: 18048644; http://dx.doi.org/10.1182/blood-2007-10-116582
PubMed Web of Science ®Google Scholar
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113:4153 - 4162; PMID: 19141862; http://dx.doi.org/10.1182/blood-2008-11-185132
PubMed Web of Science ®Google Scholar
Raff T, Gökbuget N, Lüschen S, Reutzel R, Ritgen M, Irmer S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007; 109:910 - 915; PMID: 17023577; http://dx.doi.org/10.1182/blood-2006-07-037093
PubMed Web of Science ®Google Scholar
Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219 - 225; PMID: 7602098
PubMed Web of Science ®Google Scholar
Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526 - 2534; PMID: 11588051; http://dx.doi.org/10.1182/blood.V98.8.2526
PubMed Web of Science ®Google Scholar
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 2006; 107:1564 - 1569; PMID: 16234351; http://dx.doi.org/10.1182/blood-2005-07-2738
PubMed Web of Science ®Google Scholar
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 2008; 36:997 - 1003; PMID: 18495330; http://dx.doi.org/10.1016/j.exphem.2008.03.005
PubMed Web of Science ®Google Scholar
Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541 - 552; PMID: 14527402; http://dx.doi.org/10.1016/S1097-2765(03)00350-2
PubMed Web of Science ®Google Scholar
Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610 - 1614; PMID: 19299620; http://dx.doi.org/10.1126/science.1165480
PubMed Web of Science ®Google Scholar
Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum 2010; 62:1933 - 1943; PMID: 20506263
PubMed Web of Science ®Google Scholar
Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195 - 202; PMID: 20299542; http://dx.doi.org/10.1093/protein/gzp094
PubMed Web of Science ®Google Scholar
Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68:4998 - 5003; PMID: 18593896; http://dx.doi.org/10.1158/0008-5472.CAN-07-6226
PubMed Web of Science ®Google Scholar
Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, et al. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008; 7:726 - 733; PMID: 18424917; http://dx.doi.org/10.4161/cbt.7.5.6097
PubMed Web of Science ®Google Scholar

References

Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2:129 - 136; PMID: 20190561; http://dx.doi.org/10.4161/mabs.2.2.11221
PubMed Web of Science ®Google Scholar
Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001; 49:911 - 917; PMID: 11410615; http://dx.doi.org/10.1177/002215540104900711
PubMed Web of Science ®Google Scholar
Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83:261 - 266; PMID: 10901380
PubMed Web of Science ®Google Scholar
Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246 - 1252; PMID: 10415020
PubMed Web of Science ®Google Scholar
Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526 - 2534; PMID: 11588051; http://dx.doi.org/10.1182/blood.V98.8.2526
PubMed Web of Science ®Google Scholar
Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009; 69:4270 - 4276; PMID: 19435924; http://dx.doi.org/10.1158/0008-5472.CAN-08-2861
PubMed Web of Science ®Google Scholar
Ruf P, Jäger M, Foerster B, Martinius H, Seimetz D, Lindhofer H. Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. J Clin Oncol 2011; 29
Google Scholar
Webber KO, Reiter Y, Brinkmann U, Kreitman R, Pastan I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol Immunol 1995; 32:249 - 258; PMID: 7723770; http://dx.doi.org/10.1016/0161-5890(94)00150-Y
PubMed Web of Science ®Google Scholar
Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011; 108:11187 - 11192; PMID: 21690412; http://dx.doi.org/10.1073/pnas.1019002108
PubMed Web of Science ®Google Scholar
Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011; 108:8194 - 8199; PMID: 21536919; http://dx.doi.org/10.1073/pnas.1018565108
PubMed Web of Science ®Google Scholar
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493 - 2498; PMID: 21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
PubMed Web of Science ®Google Scholar
King DJ, Adair JR, Angal S, Low DC, Proudfoot KA, Lloyd JC, et al. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment. Biochem J 1992; 281:317 - 323; PMID: 1736881
PubMed Web of Science ®Google Scholar
Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617 - 621; PMID: 8844834; http://dx.doi.org/10.1093/protein/9.7.617
PubMedGoogle Scholar
Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195 - 202; PMID: 20299542; http://dx.doi.org/10.1093/protein/gzp094
PubMed Web of Science ®Google Scholar
Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637 - 19646; PMID: 20400508; http://dx.doi.org/10.1074/jbc.M110.117382
PubMed Web of Science ®Google Scholar
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436 - 449; PMID: 20382161; http://dx.doi.org/10.1016/j.jmb.2010.04.001
PubMed Web of Science ®Google Scholar
Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, et al. Application of dual-affinity re-targeting (DART) molecules to achieve optimal redirected t-cell killing of b-cell lymphoma. Blood 2011; 117:4542 - 4551; PMID: 21300981; http://dx.doi.org/10.1182/blood-2010-09-306449
PubMed Web of Science ®Google Scholar
Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 2010; 107:22611 - 22616; PMID: 21149738; http://dx.doi.org/10.1073/pnas.1016478108
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date